Literature DB >> 12389886

Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome.

I R Whittle1, N Basu, R Grant, M Walker, A Gregor.   

Abstract

Many clinical trials have shown that the most important prognostic variable in patients with malignant glioma is advanced age. However, can some patients aged >60 years still have relatively good outcomes with conventional surgical and radiotherapeutic treatment? A previous audit of practice (1983-89) suggested that functional status was an important prognostic variable in the elderly. We have reviewed a further cohort (1989-96) to evaluate changes in practice and outcomes given advances in neuroimaging, neurosurgery and radiotherapy. The major findings in this series of 80 patients aged over 60 years with a histological diagnosis of supratentorial malignant glioma were: (i) There was a relationship between management undertaken and clinical status of the patients (p < 0.01), i.e. patients in good grade generally had tumour debulking and radiotherapy, whilst those in poor grade generally had only biopsy. (ii) There was a significant increase in survival of patients in the second period who received surgical debulking and post-operative radiotherapy (from a median of 23 to 41 weeks (p < 0.05). (iii) It is likely that case selection accounted for much of this improvement since there was a direct relationship between median survival time and good clinical grade using the WHO performance scale. (iv) A shorter radiotherapy course (30 Gy in six fractions) was as efficacious as a conventional course (60 Gy in 30 fractions), and those patients having radiotherapy survived significantly longer than those not having this treatment (p = 0.001). This study has again demonstrated the importance of preoperative clinical grade and radiotherapy treatment in determining outcomes in patients >60 years. To put these data in a societal context a recent prospective multicentre audit of patients with malignant glioma in Scotland, and another audit from our unit, showed that between 24 and 65% of patients aged >60 years, with a CT diagnosis of malignant glioma do not undergo either surgery or radiotherapy. Advanced age per se should not be a bar to interventional treatment in patients aged >60 years with suspected malignant glioma.

Entities:  

Mesh:

Year:  2002        PMID: 12389886     DOI: 10.1080/02688690021000007650

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  12 in total

1.  Palliative Radiotherapy of Primary Glioblastoma.

Authors:  Jaspar Witteler; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre.

Authors:  L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

3.  The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.

Authors:  O F Olmez; E Cubukcu; T Evrensel; M Kurt; N Avci; S Tolunay; A Bekar; A Deligonul; M Hartavi; N Alkis; O Manavoglu
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

Review 4.  Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.

Authors:  Saleh A Almenawer; Jetan H Badhiwala; Waleed Alhazzani; Jeffrey Greenspoon; Forough Farrokhyar; Blake Yarascavitch; Almunder Algird; Edward Kachur; Aleksa Cenic; Waseem Sharieff; Paula Klurfan; Thorsteinn Gunnarsson; Olufemi Ajani; Kesava Reddy; Sheila K Singh; Naresh K Murty
Journal:  Neuro Oncol       Date:  2015-01-03       Impact factor: 12.300

5.  Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort.

Authors:  S C Erridge; M G Hart; G R Kerr; C Smith; S McNamara; R Grant; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

Review 6.  Microsurgery for malignant gliomas.

Authors:  M Gazi Yaşargil; Paulo A S Kadri; Dianne C H Yasargil
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

7.  Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.

Authors:  Christian Ewelt; Mathias Goeppert; Marion Rapp; Hans-Jakob Steiger; Walter Stummer; Michael Sabel
Journal:  J Neurooncol       Date:  2010-10-16       Impact factor: 4.130

Review 8.  Radiation therapy for older adults with glioblastoma: radical treatment, palliative treatment, or no treatment at all?

Authors:  Giuseppe Minniti; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

9.  Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007).

Authors:  Fabio M Iwamoto; Anna R Cooper; Anne S Reiner; Lakshmi Nayak; Lauren E Abrey
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

10.  Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

Authors:  Kerrie L McDonald; Grace Aw; Paul Kleihues
Journal:  Front Neurol       Date:  2013-01-18       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.